Dr. Noemí Marina of Mecwins recently gave an invited presentation at the NanoBio&Med2024 conference, which took place from 5-7 November at the Parc Científic de Barcelona (PCB) in Barcelona, Spain. Her talk, entitled “Mecwins AVAC, a window opened on the world of proteins: from invading pathogens to fighter cytokines”, showcased the latest advances in Mecwins’ AVAC technology, which is designed for the ultrasensitive detection of protein biomarkers in biofluids – an essential tool for early disease diagnosis.
Mecwins’ AVAC platform, based on digital single molecule counting, offers exceptional sensitivity, wide dynamic range and multiplexing capability. These capabilities position it as a key solution for detecting low-abundance proteins, which are critical for identifying diseases such as HIV and sepsis, with greater precision than traditional assays. Dr. Marina’s presentation underscored Mecwins mission to establish AVAC as a reference technology in medical diagnostics, contributing to better health outcomes for at-risk populations.
For more information, please visit: NanoBio&Med2024 Conference
